American Peptide Company will attend CPhI Worldwide 2009

American Peptide Company to Highlight GMP Peptide Manufacturing Capabilities at CPhI Worldwide 2009

American Peptide Company, a leading provider of peptides and peptide-based services to the pharmaceutical and life science industries, will highlight its cGMP (current Good Manufacturing Practice) peptide manufacturing capabilities at CPhI Worldwide, October 13-15, 2009, in Feria de Madrid, Madrid, Spain, Hall 4, Booth #77 in the USA Pavilion.

The company’s strict compliance with cGMP guidelines ensures quality peptide products for therapeutic and diagnostic applications from the clinical trial phase to commercialization. High quality peptides help drug manufacturers realize improved consistency, with higher yields and reliable final product quality. Companies looking to commercialize their product can significantly reduce their total operations cost and time to market.

At American Peptide Company’s cGMP manufacturing facility in Vista , California , all facilities, procedures, and documentation are maintained in accordance with GMP standards as defined by the United States Code of Federal Regulations. Additionally, the company mandates application of cGMP practices to non-cGMP applications in the early phases of drug development to provide drug researchers with manufacturing processes that can be scaled up efficiently.

To better meet the needs of its growing base of customers, the company recently embarked upon a significant facility expansion at its Vista , California location, increasing large-scale GMP peptide production capacity. This expansion includes the construction of peptide purification and synthesis suites. Large-scale synthesis suites for both solution phase and solid phase peptide synthesis are also planned as part of the expansion.

The company conducts both solution phase and solid phase synthesis at the same facility, which minimizes risks associated with technology transfer, process development, and pilot scale-up. This allows American Peptide Company immerse to production campaigns and clinical batches with great success rates. This facility has capacity to synthesize gram to multi-kilogram quantities of peptides.

"As we see growth in our customer base and an increasing volume of bulk orders, we will continue to enhance our operations to better account for our customers’ needs,” says Takahiro Ogata, president and COO, American Peptide Company. “In the European market, where we are currently experiencing significant growth, our GMP peptide manufacturing capabilities enable our customers to meet their drug development and manufacturing needs."

About American Peptide Company, Inc.

American Peptide Company (APC) is a leading manufacturer of peptides and peptide conjugates. The company offers comprehensive selection of pre-manufactured catalog peptides, custom synthesis, and GMP generic peptide active pharmaceutical ingredients (APIs). Its manufacturing facility in Sunnyvale , California , offers research Grade peptides to customers, and its Vista facility, also in California , provides GMP manufacturing and services. The company also offers a portfolio of value-added services, including process development, scale-up production, analytical and process validation, stability studies, CMC, DMF, and regulatory support.

American Peptide Company is experienced in solid-phase and solution-phase peptide synthesis, as well as organic conjugations, proteins and PEGylation. As a wholly-owned subsidiary of ILS, Inc., a member of Otsuka group of Japan . APC has offices in the U.S. and representatives in Japan , South Korea , the UK , and China . APC remains dedicated to delivering high quality peptides to pharmaceutical and biotech companies worldwide. For more information, please visit www.americanpeptide.com .